(Reuters)—Amgen Inc. and UCB SA no longer expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial. The drug, romosozumab, which would be sold under the brand name Evenity if approved, is awaiting an approval decision by the…
Search results for: bone
MicroRNAs Provide Insight into Bone Metabolism
A recent study examined the functional variants within microRNAs that affect bone metabolism and possibly bone disorders. Researchers found overexpression of microRNAs may contribute to the osteoporotic phenotype, and the gene targets associated with two specific osteoblast-expressed microRNAs may be critical in osteoporosis…
Alterations in the Microbiome Are Associated with Changes in Bone Quality
By treating mice with antibiotics, researchers found that alterations in the gut microbiome impaired the mechanical properties of bone and depleted splenic B and T cell populations. The researchers suspect the decrease in bone strength resulted from the change in the immune system…
On the Road in Rajasthan: Vehicular-Caused Bone, Joint Damage in India
In the good old days, physicians routinely made house calls. The decision to visit the literal bedside of a patient was practical: hospital services were primitive and often offered too little benefit to justify an emergency journey by the patient. These physicians carried leather bags, sometimes called Gladstones, that were filled with instruments for eventualities…
The ACR Teams with National Bone Health Alliance to Increase Focus on Osteoporosis, Bone Disease
Bone health in general, and osteoporosis in particular, is among the most common conditions seen in rheumatology practices. The ACR recently joined the National Bone Health Alliance (NBHA) to reach out to other stakeholders. “In 2004, the Surgeon General of the United States published a report on osteoporosis that discussed in depth the gaps in…
SSRIs Act Centrally to Cause Bone Loss
In a recent study, investigators examined the effects of both the short- and long-term use of selective serotonin-reuptake inhibitors (SSRIs) on the development and loss of bone. The study results describe the mechanisms by which SSRIs, specifically fluoxetine, affect osteoclasts short term to increase bone mass, but also how the treatment may cause bone loss at six weeks in mice…
Proton Pump Inhibitor Use May Be Linked to Bone Mineral Density
The use of proton pump inhibitors may lead to changes in bone mineral density and an increased risk of developing osteoporosis…
Women on Osteoporosis Drugs Still Need Bone Density Screenings
(Reuters Health)—Women with osteoporosis who take bisphosphonates to help avoid fractures still need to have their bone density monitored, a Canadian study suggests. Researchers who studied more than 6,600 women taking osteoporosis drugs found that for nearly one in five, bone mineral density at the hip actually decreased after the women started taking the medication….
The Gut Microbiome Influences Postmenopausal Bone Loss
Bone health has been successfully improved by using probiotics to influence the gut microbiome in postmenopausal women with osteoporosis. New research has gained insight into this process, uncovering that sex steroid depletion increases gut permeability resulting in inflammation and pathology in mice. Treatment with probiotics also prevents this increase in gut permeability and bone loss associated with sex steroid depletion…
Extra Bone Resorption in Pregnancy, Lactation May Pass Maternal Lead Burden to Baby
NEW YORK (Reuters Health)—Bone resorption increases during pregnancy and continues to be high postpartum, according to new findings using lead testing to measure bone turnover. Researchers also found unexpected evidence that maternal lead burden is transferred to the fetus. “These data confirm calcium balance studies that indicate increased bone resorption throughout pregnancy and lactation,” Dr….
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 103
- Next Page »